MedTrace Logo

The Effect of Hypoxia on Type 2 Diabetes and Weight Loss

NCT05147116 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-01-24

Study results available
· View outcomes & findings →

Summary

The number of people with type 2 diabetes mellitus (T2DM) continuing to rise, this pandemic is expected to reach 700 million people by 2045. T2DM is a metabolic condition characterized by progressive insulin resistance and chronic hyperglycemia (high blood glucose concentrations). Hyperglycaemia increases the risk of both micro- and macrovascular damage, whilst interventions that reduce blood glucose mitigate this risk. Weight loss, achieved through exercise and dietary modification, is effective at reducing hyperglycaemia. However, despite the clear benefits of exercise and weight loss, diverse psychological, sociological and logistical factors can make it difficult for some individuals with T2DM to initiate, or adhere to, these lifestyle interventions. Alternative approaches to treatment are therefore required.

The purpose of this research project is to investigate whether 10-days of overnight exposure to moderate hypoxia is effective at improving blood glucose control in individuals with T2DM and to provide insight into the physiological mechanisms responsible for any beneficial effects.

Conditions

  • Type2 Diabetes

Interventions

OTHER

Sleeping in a tent

Participants will spend 10 consecutive nights of sleeping in a tent

Sponsors & Collaborators

  • Bournemouth University

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • University of Cambridge

    collaborator OTHER

  • Portsmouth Hospitals NHS Trust

    collaborator OTHER_GOV

  • University of Portsmouth

    lead OTHER

Principal Investigators

  • Anthony Shepherd, PhD · University of Portsmouth

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2023-01-30
Completion
2023-01-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05147116 on ClinicalTrials.gov